Phillip A Engen

Mr. Phillip A Engen

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in Environmental Pollution
Verified
Journal Article
Closed access
EMEce A. Mutlu
Ece A. Mutlu
ICIşın Y. Comba
Işın Y. Comba
TCTakugo Cho
Takugo Cho
PEPhillip A Engen
Phillip A Engen
CYCemal Yazıcı
Cemal Yazıcı
GMGökhan M. Mutlu
Gökhan M. Mutlu

1 January 2011 in Particle and Fibre Toxicology
Verified
Journal Article
Open access
PDF file
EMEce A. Mutlu
Ece A. Mutlu
PEPhillip A Engen
Phillip A Engen
SSSaul Soberanes
Saul Soberanes
DUDaniela Urich
Daniela Urich
CFChristopher B. Forsyth
Christopher B. Forsyth
GMGökhan M Mutlu
Gökhan M Mutlu
Exposure to particulate matter (PM) air pollution may be an important environmental factor leading to exacerbations of inflammatory illnesses in the GI tract. PM can gain access to the gastrointestinal (GI) tract via swallowing of air or secretions from the upper airways or mucociliary clearance of inhaled particles.

16 February 2018 in Genes
Verified
Journal Article
Open access
PDF file
FBFaraz Bishehsari
Faraz Bishehsari
PEPhillip A Engen
Phillip A Engen
NPNailliw Z. Preite
Nailliw Z. Preite
Yunus Emre TunçilYunus Emre Tunçil
Yunus Emre Tunçil
ANAnkur Naqib
Ankur Naqib
AKAli Keshavarzian
Ali Keshavarzian
Epidemiological studies propose a protective role for dietary fiber in colon cancer (CRC). One possible mechanism of fiber is its fermentation property in the gut and ability to change microbiota composition and function. Here, we investigate the role of a dietary fiber mixture in polyposis and elucidate potential mechanisms using TS4Cre × cAPCl°x468 mice. Stool microbiota profiling was performed, while functional prediction was done using PICRUSt. Stool short-chain fatty acid (SCFA) metabolites were measured. Histone acetylation and expression of SCFA butyrate receptor were assessed. We found that SCFA-producing bacteria were lower in the polyposis mice, suggesting a decline in the fermentation product of dietary fibers with polyposis. Next, a high fiber diet was given to polyposis mice, which significantly increased SCFA-producing bacteria as well as SCFA levels. This was associated with an increase in SCFA butyrate receptor and a significant decrease in polyposis. In conclusion, we found polyposis to be associated with dysbiotic microbiota characterized by a decline in SCFA-producing bacteria, which was targetable by high fiber treatment, leading to an increase in SCFA levels and amelioration of polyposis. The prebiotic activity of fiber, promoting beneficial bacteria, could be the key mechanism for the protective effects of fiber on colon carcinogenesis. SCFA-promoting fermentable fibers are a promising dietary intervention to prevent CRC.

18 February 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
DHDeborah A. Hall
Deborah A. Hall
RVRobin M. Voigt
Robin M. Voigt
TCThaisa M. Cantu-Jungles
Thaisa M. Cantu-Jungles
BHBruce Hamaker
Bruce Hamaker
PEPhillip A Engen
Phillip A Engen
AKAli Keshavarzian
Ali Keshavarzian
A pro-inflammatory intestinal microbiome is characteristic of Parkinson’s disease (PD). Prebiotic fibers change the microbiome and this study sought to understand the utility of prebiotic fibers for use in PD patients. The first experiments demonstrate that fermentation of PD patient stool with prebiotic fibers increased the production of beneficial metabolites (short chain fatty acids, SCFA) and changed the microbiota demonstrating the capacity of PD microbiota to respond favorably to prebiotics. Subsequently, an open-label, non-randomized study was conducted in newly diagnosed, non-medicated (n = 10) and treated PD participants (n = 10) wherein the impact of 10 days of prebiotic intervention was evaluated. Outcomes demonstrate that the prebiotic intervention was well tolerated (primary outcome) and safe (secondary outcome) in PD participants and was associated with beneficial biological changes in the microbiota, SCFA, inflammation, and neurofilament light chain. Exploratory analyses indicate effects on clinically relevant outcomes. This proof-of-concept study offers the scientific rationale for placebo-controlled trials using prebiotic fibers in PD patients. ClinicalTrials.gov Identifier: NCT04512599.

1 March 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LXLing Xiao
Ling Xiao
BLBelinda Van't Land
Belinda Van't Land
PEPhillip A Engen
Phillip A Engen
ANAnkur Naqib
Ankur Naqib
SGStefan J. Green
Stefan J. Green
GFGert Folkerts
Gert Folkerts
Development of Type 1 diabetes (T1D) is influenced by non-genetic factors, such as optimal microbiome development during early life that “programs” the immune system. Exclusive and prolonged breastfeeding is an independent protective factor against the development of T1D, likely via bioactive components. Human Milk Oligosaccharides (HMOS) are microbiota modulators, known to regulate immune responses directly. Here we show that early life provision (only for a period of six weeks) of 1% authentic HMOS (consisting of both long-chain, as well as short-chain structures), delayed and suppressed T1D development in non-obese diabetic mice and reduced development of severe pancreatic insulitis in later life. These protective effects were associated with i) beneficial alterations in fecal microbiota composition, ii) anti-inflammatory microbiota-generating metabolite (i.e. short chain fatty acids (SCFAs)) changes in fecal, as well as cecum content, and iii) induction of anti-diabetogenic cytokine profiles. Moreover, in vitro HMOS combined with SCFAs induced development of tolerogenic dendritic cells (tDCs), priming of functional regulatory T cells, which support the protective effects detected in vivo. In conclusion, HMOS present in human milk are therefore thought to be vital in the protection of children at risk for T1D, supporting immune and gut microbiota development in early life.

24 January 2023 in Movement Disorders
Verified
Journal Article
Open access
JBJoseph C. Boktor
Joseph C. Boktor
GSGil Sharon
Gil Sharon
LMLeo A. Verhagen Metman
Leo A. Verhagen Metman
DHDeborah A. Hall
Deborah A. Hall
PEPhillip A Engen
Phillip A Engen
SMSarkis K. Mazmanian
Sarkis K. Mazmanian
Background: The gut microbiome is altered in several neurologic disorders, including Parkinson's disease (PD).Objectives: The aim is to profile the fecal gut metagenome in PD for alterations in microbial composition, taxon abundance, metabolic pathways, and microbial gene products, and their relationship with disease progression.Methods: Shotgun metagenomic sequencing was conducted on 244 stool donors from two independent cohorts in the United States, including individuals with PD (n = 48, n = 47, respectively), environmental household controls (HC, n = 29, n = 30), and community population controls (PC, n = 41, n = 49). Microbial features consistently altered in PD compared to HC and PC subjects were identified. Data were cross‐referenced to public metagenomic data sets from two previous studies in Germany and China to determine generalizable microbiome features.Results: We find several significantly altered taxa between PD and controls within the two cohorts sequenced in this study. Analysis across global cohorts returns consistent changes only in Intestinimonas butyriciproducens. Pathway enrichment analysis reveals disruptions in microbial carbohydrate and lipid metabolism and increased amino acid and nucleotide metabolism in PD. Global gene‐level signatures indicate an increased response to oxidative stress, decreased cellular growth and microbial motility, and disrupted intercommunity signaling.Conclusions: A metagenomic meta‐analysis of PD shows consistent and novel alterations in functional metabolic potential and microbial gene abundance across four independent studies from three continents. These data reveal that stereotypic changes in the functional potential of the gut microbiome are a consistent feature of PD, highlighting potential diagnostic and therapeutic avenues for future research. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.